FDA Launches New Program to Advance Neuroscience Medical Product Development
正文 · 中文译文
FDA新闻发布 FDA启动新项目以推进神经科学医疗产品开发 神经科学促进与创新枢纽将协调该机构针对脑及神经系统疾病的行动，首期聚焦于阿尔茨海默病的预防 更多新闻公告 立即发布： 2026年10月22日 美国食品药品监督管理局今日宣布启动神经科学促进与创新枢纽（NAIN），这是一个与该机构隶属于特朗普政府领导下加速医疗创新并交付突破性疗法的工作相一致的新项目。NAIN旨在推进支持针对脑及神经系统疾病医疗产品开发所需的科学、工具和监管方法。NAIN的首期项目——阿尔茨海默病预防加速器——将聚焦于推进有助于延迟或预防阿尔茨海默病的医疗产品。这两项工作均支持《国家阿尔茨海默病项目法案》（NAPA），该法案是联邦政府针对阿尔茨海默病及相关痴呆症采取协调行动的综合路线图。 “NAIN的启动反映了FDA的承诺——支持特朗普政府推动医疗创新转型——确保我们的监管科学和跨中心合作能够跟上神经科学领域的快速进展，”FDA代理局长Kyle Diamantas（法学博士）表示。“通过NAIN和阿尔茨海默病预防加速器，我们将FDA的全部专业知识应用于我们这个时代最紧迫的公共卫生挑战之一。” 为神经科学适应症开发医疗产品面临复杂的科学和临床挑战，包括对潜在生物学机制的理解有限、疾病表现的变异性，以及难以证明有意义的临床获益，特别是对于多年发展的疾病。然而，生物标志物、数字健康技术和其他医疗产品开发工具的进步为解决这些挑战提供了重要机遇。 NAIN将汇集美国食品药品监督管理局（FDA）药物评价与研究中心、生物制品评价与研究中心以及器械与放射健康中心的科学与监管专业知识，以解决那些需要跨药物、生物制品和器械协调考虑的科学与监管问题。NAIN将涵盖广泛影响大脑和神经系统的疾病，包括神经与精神疾病、物质使用障碍及疼痛。NAIN还将支持与患者、产业界、学术界及其他利益相关方的深入合作，以推进这些工作。 作为其首项举措，NAIN正在启动“阿尔茨海默病预防加速器”。这一首倡举措将汲取FDA各方的观点，并与患者和照护者、研究人员、产业界、公私合作伙伴关系及其他政府机构开展合作。该举措将探索推进阿尔茨海默病预防和早期干预药物开发临床试验的创新方法，重点关注试验人群、分期相适应的终点，以及用于证明延缓或预防阿尔茨海默病所致认知衰退的循证方法。 FDA长期以来一直致力于支持开发安全有效的医疗产品，以应对大脑和神经系统的疾病与状况。通过NAIN和阿尔茨海默病预防加速器，该机构正采取积极主动、协调一致的方法来加速进展，汇集其科学与监管专业知识， engaging 更广泛的研究与开发社区，并与联邦合作伙伴协同工作，以应对这一公共卫生挑战的规模。 媒体： FDA征求意见 202-690-6343 消费者： 888-INFO-FDA FDA是美国卫生与公众服务部下属机构，通过确保人用和兽用药物、疫苗及其他人类用生物制品和医疗器械的安全性、有效性和安全性来保护公众健康。该机构还负责国家食品供应、化妆品、膳食补充剂、辐射-emitting电子产品的安全保障，以及对烟草产品的监管。 ### 内容当前更新于： 2026年10月22日 受监管产品 生物制品 药物 医疗器械 关注FDA 在X上关注 @US_FDA 在Facebook上关注FDA 在X上关注 @FDAMedia
正文 · 英文原文
FDA News Release FDA Launches New Program to Advance Neuroscience Medical Product Development Neuroscience Advancement and Innovation Nexus to coordinate agency action on brain and nervous system conditions, with inaugural focus on Alzheimer's prevention More Press Announcements For Immediate Release: October 22, 2026 The U.S. Food and Drug Administration today announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments. NAIN is designed to advance the science, tools, and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system. NAIN’s inaugural initiative, the Alzheimer's Prevention Accelerator, will focus on advancing medical products that help delay or prevent Alzheimer's disease. Both efforts support the National Alzheimer’s Project Act (NAPA), the federal government's comprehensive roadmap for coordinated action on Alzheimer's and related dementias. "The launch of NAIN reflects FDA's commitment — in support of the Trump Administration’s drive to transform health care innovation — to making sure our regulatory science and cross-center collaboration keep pace with the rapid advances happening in neuroscience," said Acting FDA Commissioner Kyle Diamantas, J.D. "Through NAIN and the Alzheimer's Prevention Accelerator, we are bringing the full breadth of FDA's expertise to bear on one of the most urgent public health challenges of our time.” Developing medical products for neuroscience indications is associated with complex scientific and clinical challenges, including limited understanding of underlying biology, variable disease presentation, and difficulties in demonstrating meaningful clinical benefit, particularly for conditions that develop over many years. Advances in biomarkers, digital health technologies, and other medical product development tools, however, offer important opportunities to address these challenges. NAIN will bring together scientific and regulatory expertise from the FDA's Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health to address scientific and regulatory questions that benefit from coordinated consideration across drugs, biologics, and devices. NAIN will encompass conditions that affect the brain and nervous system broadly, including neurologic and psychiatric disorders, substance use disorders, and pain. NAIN will also support robust engagement with patients, industry, academia and other stakeholders to advance these efforts. As its first initiative, NAIN is launching the Alzheimer's Prevention Accelerator. This inaugural initiative will draw on perspectives from across the FDA and engage patients and caregivers, researchers, industry, public-private partnerships and other government agencies. The initiative will explore innovative approaches to advancing clinical trials for Alzheimer’s disease prevention and early-intervention drug development with emphasis on trial populations, stage-appropriate endpoints, and evidentiary approaches for demonstrating prevention or delay of cognitive decline due to Alzheimer’s disease. The FDA has long been committed to supporting the development of safe and effective medical products that address diseases and conditions of the brain and nervous system. Through NAIN and the Alzheimer's Prevention Accelerator, the agency is taking a proactive, coordinated approach to accelerating progress, bringing together its scientific and regulatory expertise, engaging the broader research and development community, and working in concert with federal partners to meet the scale of this public health challenge. Media: FDA Request for Comment 202-690-6343 Consumer: 888-INFO-FDA The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. ### Content current as of: 10/22/2026 Regulated Product(s) Biologics Drugs Medical Devices Follow FDA Follow @US_FDA on X Follow FDA on Facebook Follow @FDAMedia on X
摘要 待译
FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.